Loading...
•
Sep 30, 2024
Johnson & Johnson Q3 2024 Earnings Report
Johnson & Johnson reported strong Q3 2024 results, driven by growth in operational sales and pipeline advancements.
Key Takeaways
Johnson & Johnson's Q3 2024 results showed a 5.2% increase in reported sales to $22.5 billion. EPS decreased by 34.3% to $1.11, while adjusted EPS decreased by 9.0% to $2.42. The company has increased its full-year 2024 operational sales guidance and updated its adjusted operational EPS guidance.
Reported sales grew by 5.2% to $22.5 billion.
Operational sales grew by 6.3%.
EPS decreased by 34.3% to $1.11, while adjusted EPS decreased by 9.0% to $2.42.
Full-year 2024 operational sales guidance was increased.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Johnson & Johnson updated its 2024 guidance, including adjusted operational EPS guidance, to reflect improved performance and the impact from the recent acquisition of V-Wave.
Positive Outlook
- Adjusted Operational Sales are expected to be $89.4B – $89.8B.
- Operational Sales are expected to grow 6.3% – 6.8%.
- Estimated Reported Sales are expected to be $88.4B – $88.8B.
- Adjusted Operational EPS (Diluted) are expected to be $9.86 – $9.96.
- Adjusted EPS (Diluted) are expected to be $9.88 – $9.98.
Challenges Ahead
- M&A impact (V-Wave) is expected to be a loss of $0.24 in Adjusted Operational EPS.
- Adjusted Operational EPS (Diluted) are expected to decrease (0.6)% – 0.4%.
- Adjusted EPS (Diluted) are expected to decrease (0.4)% – 0.6%.
- Costs associated with the acquisition of V-Wave more than offset the improvement
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...